This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human IL-5 R alpha / CD125 Protein, Fc Tag
catalog :
ILA-H5259
quantity :
1 mg, 50 ug
price :
2400 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
ILA-H5259
product name :
Human IL-5 R alpha / CD125 Protein, Fc Tag
quantity :
1 mg, 50 ug
price :
2400 USD, 350 USD
quantity & price :
$350/50ug,$2400/1mg (250ug × 4)
target :
IL-5 R alpha
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
Human IL-5 R alpha, Fc Tag (ILA-H5259) is expressed from human 293 cells (HEK293). It contains AA Asp 21 - Trp 342 (Accession # Q01344-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human IL-5 R alpha, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Interleukin-5 receptor subunit alpha (IL5RA) is also known as IL-5 receptor subunit alpha, IL-5R subunit alpha and CD125,which is a single-pass type I membrane protein that belongs to the type I cytokine receptor family and type 5 subfamily.IL5R, a heterodimer of an alpha and a beta subunit, is expressed on eosinophils and basophils. IL5RA / CD125 is the receptor for interleukin-5 (IL5) and the alpha chain can bind to IL5. The WSXWS motif of IL5RA appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.The beta subunit of IL5R is common to the IL3, IL5 and GM-CSF receptors.
References :
(1) Tavernier J., ET AL., 1991, Cell 66:1175-1184.
(2) Patino E., et al., 2011, Structure 19:1864-1875.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments